Considerations and caveats in anti-virulence drug development.
Considerations and caveats in anti-virulence drug development.
复制标题
DOI：
10.1016/j.mib.2016.06.001
复制
发表时间：
2016-10
影响因子：
5.4
通讯作者：
Rahme LG
中科院分区：
文献类型：
--
作者：
Maura D;Ballok AE;Rahme LG
As antibiotic resistance remains a major public health threat, anti-virulence therapy research is gaining interest. Hundreds of potential anti-virulence compounds have been examined, but very few have made it to clinical trials and none have been approved. This review surveys the current anti-virulence research field with a focus on the highly resistant and deadly ESKAPE pathogens, especially Pseudomonas aeruginosa. We discuss timely considerations and caveats in anti-virulence drug development, including target identification, administration, preclinical development, and metrics for success in clinical trials. Development of a defined pipeline for anti-virulence agents, which differs in important ways from conventional antibiotics, is imperative for the future success of these critically needed drugs.
登录
查看更多内容
革兰氏阴性细菌毒力蛋白分泌的抑制剂。
影响因子：
30.3
作者：
Felise HB;Nguyen HV;Pfuetzner RA;Barry KC;Jackson SR;Blanc MP;Bronstein PA;Kline T;Miller SI
通讯作者：
Miller SI
影响因子：
6.7
作者：
Ilangovan A;Fletcher M;Rampioni G;Pustelny C;Rumbaugh K;Heeb S;Cámara M;Truman A;Chhabra SR;Emsley J;Williams P
通讯作者：
Williams P
影响因子：
11.8
作者：
Kang, CI;Kim, SH;Choe, KW
通讯作者：
Choe, KW
影响因子：
6.7
作者：
Kesarwani, Meenu;Hazan, Ronen;Rahme, Laurence G.
通讯作者：
Rahme, Laurence G.
影响因子：
15
作者：
Amara, Neri;Mashiach, Roi;Meijler, Michael M.
通讯作者：
Meijler, Michael M.